1. 475 F Supp 838 (DDC 1979).
2. U.S. Food and Drug Administration. Drug Safety Communication: Reports of a rare, but serious and potentially fatal adverse effect with the use of over-the-counter (OTC) benzocaine gels and liquids applied to the gums or mouth. April 7, 2011. Available at: http://www.fda.gov/drugs/drugsafety/ucm250024.htm. Accessed February 6, 2023.
3. CDRH’s Division of Industry Communication and Education (DICE). The FDA warns against use of previously owned test strips or test strips not authorized for sale in the United States: FDA Safety Communication. April 8, 2019. Available at: https://www.fda.gov/medical-devices/safety-communications/fda-warns-against-use-previously-owned-test-strips-or-test-strips-not-authorized-sale-united-states. Accessed February 6, 2023.
4. Skinner W. Allowable advertising claims for dietary supplements. J Pharm Law. 1996;5(2):309–326.
5. APhA policy supports a third class of drugs. Am Pharm. 1991;31(2):40.